100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.

[1]  April M. Kloxin,et al.  Metastatic melanoma - a review of current and future treatment options. , 2015, Acta dermato-venereologica.

[2]  S. Martinez,et al.  Erratum: Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream (Melanoma Research (2011) 21 (235-243)) , 2013 .

[3]  D. Goldgar,et al.  A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. , 2012, Archives of dermatology.

[4]  C. Temple,et al.  Intra‐lesional interleukin‐2 for the treatment of in‐transit melanoma , 2011, Journal of surgical oncology.

[5]  M. Fung,et al.  Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream , 2011, Melanoma research.

[6]  C. Garbe,et al.  High response rate after intratumoral treatment with interleukin‐2 , 2010, Cancer.

[7]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Dalgleish,et al.  Topical imiquimod and intralesional interleukin‐2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma , 2008, The British journal of dermatology.

[9]  A. Dalgleish,et al.  Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma , 2007, The British journal of dermatology.

[10]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[12]  G. Stingl,et al.  Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod1 , 2004, The Journal of Immunology.

[13]  J. Overgaard,et al.  Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2. , 2004, European journal of cancer.

[14]  C. Garbe,et al.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.

[15]  T. Osaki,et al.  Apoptosis induction by interleukin‐2‐activated cytotoxic lymphocytes in a squamous cell carcinoma cell line and Daudi cells – involvement of reactive oxygen species‐dependent cytochrome c and reactive oxygen species‐independent apoptosis‐inducing factors , 2003, Immunology.

[16]  B. King,et al.  Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines. , 2014, Dermatology online journal.